Northwest Biotherapeutics | NWBO - Operating Profit


Northwest Biotherapeutics reported $-14.8M in Operating Profit for its fiscal quarter ending in September of 2024.





Operating Profit Change Date
Agenus USD -13.31M 12.58M Mar/2025
AstraZeneca USD 2.97B 4.48B Dec/2025
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Celldex Therapeutics USD -73.62M 9.76M Sep/2025
Eisai JPY 20.03B 6.36B Dec/2025
Infinity Pharmaceuticals USD -10.12M 1.39M Jun/2023
Merck USD 6.24B 318M Dec/2025
Northwest Biotherapeutics USD -14.8M 2.66M Sep/2024
Pfizer USD 4.65B 3.99B Dec/2025
Roche Holding CHF 9.56B 3.8B Dec/2025